NetworkNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety studies and key toxicology programs.
The editorial highlighted more than a decade of preclinical research supporting Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated and chronic inflammatory disease treatment markets.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing Lucid-MS, a patented first-in-class drug candidate designed to directly protect the myelin sheath damaged by multiple sclerosis (“MS”), according to an AINewsWire editorial. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound intended to prevent myelin degradation. The company recently filed an Investigational New Drug application with the U.S. Food and Drug Administration and is preparing for a phase 2 clinical trial following successful completion of phase 1 safety studies and key toxicology programs.
The editorial highlighted more than a decade of preclinical research supporting Lucid-MS, including studies showing preservation of myelin integrity, reduced degradation and improved functional recovery in animal models. Quantum BioPharma is also collaborating with Massachusetts General Hospital on validation of a novel PET imaging technique designed to directly measure myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies. The report also noted recent clinical and regulatory developments from Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX) and Bristol Myers Squibb Company (NYSE: BMY), underscoring continued innovation across autoimmune, immune-mediated and chronic inflammatory disease treatment markets.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
